Literature DB >> 32779522

Clinical and MRI characteristics of multiple sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada.

Estelle Seyman1, Ashley Jones2, Melanie Guenette2, Reza Vosoughi2, Daniel Selchen2, Lilyana Amezcua3, Stefan Baral4, Jiwon Oh2.   

Abstract

BACKGROUND: Multiple sclerosis (MS) incidence is rising in traditionally low-burden regions, including the Middle East and North Africa (MENA).
OBJECTIVES: Our objective was to evaluate disease characteristics in MS patients of MENA descent (MENA-MS).
METHODS: MENA-MS patients and age- and sex-matched MS patients of European descent (EUR-MS) were identified through the MS Clinic Registry of St. Michael's Hospital in Toronto, Canada. Disease activity and severity were evaluated by the annualized relapse rate (ARR), magnetic resonance imaging (MRI) activity, change in the Expanded Disability Status Scale (EDSS), progression index (PI), and MS Severity Score (MSSS).
RESULTS: All MS patients within the registry identified to be of MENA origin (n = 192), and age- and sex-matched EUR-MS patients were included. Mean age was 42.9 years, 67% female. A total of 25% and 24% of EUR-MS and MENA-MS had progressive disease, with similar mean disease durations (11.5 and 11.4 years, respectively). Clinical and radiological disease activity (ARR, proportion with new/enlarging MRI lesions) was similar. MENA-MS showed greater disability progression over time (EDSS change = 0.24 vs. 0.06, p = 0.01), a higher MSSS (3.12 vs. 2.67, p = 0.04), and higher PI (0.34 vs. 0.27, p = 0.07).
CONCLUSION: MENA-MS patients demonstrate higher disease severity compared to EUR-MS patients, despite having similar inflammatory measures of disease activity, with disability progression in the absence of relapses. These observations illustrate the importance of the intersections of environmental, socioeconomic, and genetic determinants in optimizing individualized MS care.

Entities:  

Keywords:  Middle East; Multiple sclerosis; North Africa; epidemiology; natural history studies; precision medicine

Year:  2020        PMID: 32779522     DOI: 10.1177/1352458520948212

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

1.  Is It Time for Quotas to Achieve Racial and Ethnic Representation in Multiple Sclerosis Trials?

Authors:  Farrah J Mateen
Journal:  Front Neurol       Date:  2021-05-13       Impact factor: 4.003

2.  Differences in MS clinical and epidemiological characteristics between Ashkenazi and non-Ashkenazi Jewish patients in Israel: a retrospective single center study.

Authors:  Arnon Karni; Gil Ben Noon; Tamara Shiner; Ifat Vigiser; Hadar Kolb; Keren Regev
Journal:  Sci Rep       Date:  2022-03-16       Impact factor: 4.379

Review 3.  How Does the Immune System Enter the Brain?

Authors:  Josephine A Mapunda; Houyam Tibar; Wafa Regragui; Britta Engelhardt
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.